Achaogen is dedicated to addressing serious medical needs caused by the development of bacterial resistance to antibiotics.
According to the CDC, over 70% of hospital bacterial infections are resistant to one or more classes of antibacterial drugs. In the United States alone, these infections cause more than 90,000 deaths per year and result in $4.5 billion in excess healthcare costs.
Achaogen exists to apply its anticipatory science to the creation of novel medical therapies to combat tomorrow’s drug-resistant pathogens, specifically, the next generation of pan-resistant bacteria, including infections caused by Gram-negative pathogens and methicillin-resistant Staphylococcus aureus (MRSA). This scientific strategy represents a novel approach to addressing the global bacterial-resistance crisis.
Company Growth (employees)
South San Francisco, US